"we were quite surprised to find there were no significant differences," says study author.
researchers examined 1,714 samples over six months and found that just 39 per cent contained what they buyer thought they had been sold
may 17, 2018 -- the fda has approved the first in a new class of migraine drugs that aim to fight painful